Reporting owner · CIK 0001813058

Bair Teresa Brophy

Visual SEC Form 4 history across 1 companies, 9 transactions and 5 filings.

CLOChief Legal OfficerKura Oncology, Inc.
Open-market mix
Filings5Form 4 records
Buying$00 purchases
Selling$455K3 sales
Net value−$455KBuys minus sells
Companies12 securities
Most recentAug 19, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-5Jan 242Jan 25Jan 261Aug 26

Net value flow

Buys minus sells

Jan 24
$0
Jan 25
−$57.3K
Jan 26
$0
Aug 26
−$397.7K

Transaction texture

Ownership and ticket size

Average P/S size$151.7K
Median P/S size$38.1K
Direct9
Indirect0
Aug 19, 2026sale

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Kura Oncology, Inc. on Aug 19, 2026 valued at $397,681.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Kura Oncology, Inc. on Aug 19, 2026 valued at $397,681.

Review SEC filing

Associated companies

Visual map of known reporting history

Bair Teresa Brophy Insider Activity FAQ

SEC Form 4 context

Who is Bair Teresa Brophy?

Bair Teresa Brophy is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001813058.

Which companies has Bair Teresa Brophy reported transactions for?

Kura Oncology, Inc.

When was Bair Teresa Brophy's latest insider buy?

No open-market insider purchase is available for this period.

When was Bair Teresa Brophy's latest insider sale?

sale at Kura Oncology, Inc. on Aug 19, 2026 valued at $397,681.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.